Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease who are eligible to receive the drug.

"It’s crucial that patients and their families know about this new option," said Dr. William Russell, an oncology radiologist ...

A technique to preserve nerves during prostate cancer surgery almost doubles the proportion of men who keep erectile function ...

The Bishop of Manchester has revealed he has been diagnosed with prostate cancer. The Right Reverend David Walker said the ...

On March 28, the Food and Drug Administration approved Pluvicto, a new radiation agent able to treat patients with prostate ...

Moderately hypofractionated and conventionally fractionated radiotherapy demonstrate similar efficacy, but one ...

Recovering erections grabs the attention of most men and their doctors after prostate cancer treatment. A new study redirects ...

Men who avoided prostate cancer screening appointments were significantly more likely to die from the disease, according to ...

Prostate cancer is one of the most common cancers that occur in men. While it can be life-threatening, the disease is ...

Use of NeuroSAFE to guide nerve sparing during robot-assisted radical prostatectomy improved patient-reported erectile ...

The OPTIMUM study found 4.5% more clinically significant cancers among men who underwent micro-ultrasound–guided biopsies of ...